Literature DB >> 20010623

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.

D K Hiwase, D White, S Zrim, V Saunders, J V Melo, T P Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20010623     DOI： 10.1038/leu.2009.242

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Authors:  Sung-Han Hsiao; Sabrina Lusvarghi; Yang-Hui Huang; Suresh V Ambudkar; Sheng-Chieh Hsu; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2019-01-11       Impact factor: 8.679

Review 2.  ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Authors:  Jiexin Deng; Jie Shao; John S Markowitz; Guohua An
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

3.  Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.

Authors:  Ahmet Tunceroglu; Michiyuki Matsuda; Raymond B Birge
Journal:  Mol Cancer Ther       Date:  2010-09-03       Impact factor: 6.261

Review 4.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 5.  Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.

Authors:  Suneet Shukla; Zhe-Sheng Chen; Suresh V Ambudkar
Journal:  Drug Resist Updat       Date:  2012-02-09       Impact factor: 18.500

6.  Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Authors:  Devendra K Hiwase; Verity A Saunders; Eva Nievergall; Douglas D Ross; Deborah L White; Timothy P Hughes
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

7.  Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Authors:  F J Giles; E Abruzzese; G Rosti; D-W Kim; R Bhatia; A Bosly; S Goldberg; G L S Kam; M Jagasia; W Mendrek; T Fischer; T Facon; U Dünzinger; D Marin; M C Mueller; Y Shou; N J Gallagher; R A Larson; F-X Mahon; M Baccarani; J Cortes; H M Kantarjian
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

8.  Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.

Authors:  Stefan Balabanov; Artur Gontarewicz; Gunhild Keller; Laura Raddrizzani; Melanie Braig; Roberta Bosotti; Jürgen Moll; Edgar Jost; Christine Barett; Imke Rohe; Carsten Bokemeyer; Tessa L Holyoake; Tim H Brümmendorf
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

9.  The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia.

Authors:  Yu Zhu; Liangqin Pan; Ming Hong; Weixing Liu; Chun Qiao; Jianyong Li; Sixuan Qian
Journal:  J Biomed Res       Date:  2014-09-07

10.  Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.

Authors:  Thomas O'Hare; Christopher A Eide; Anupriya Agarwal; Lauren T Adrian; Matthew S Zabriskie; Ryan J Mackenzie; Dorian H Latocha; Kara J Johnson; Huihong You; Jenny Luo; Steven M Riddle; Bryan D Marks; Kurt W Vogel; Dennis R Koop; John Apgar; Jeffrey W Tyner; Michael W Deininger; Brian J Druker
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.